About Grifols SA, Barcelona (NASDAQ:GRFS)
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Industry, Sector and Symbol
Trailing P/E Ratio22.6774193548387
Forward P/E Ratio17.72
Sales & Book Value
Annual Sales$4.88 billion
Price / Sales2.95
Cash Flow$1.44 per share
Price / Cash14.64
Book Value$6.02 per share
Price / Book3.50
Net Income$749.04 million
Return on Equity18.08%
Return on Assets6.22%
Grifols SA, Barcelona (NASDAQ:GRFS) Frequently Asked Questions
What is Grifols SA, Barcelona's stock symbol?
Grifols SA, Barcelona trades on the NASDAQ under the ticker symbol "GRFS."
How often does Grifols SA, Barcelona pay dividends? What is the dividend yield for Grifols SA, Barcelona?
Grifols SA, Barcelona declared a semiannual dividend on Friday, May 26th. Stockholders of record on Thursday, June 1st will be paid a dividend of $0.122 per share on Thursday, June 8th. This represents a dividend yield of 1.54%. The ex-dividend date is Tuesday, May 30th. View Grifols SA, Barcelona's Dividend History.
When did Grifols SA, Barcelona's stock split? How did Grifols SA, Barcelona's stock split work?
Grifols SA, Barcelona shares split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were issued to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols SA, Barcelona stock prior to the split would have 200 shares after the split.
Where is Grifols SA, Barcelona's stock going? Where will Grifols SA, Barcelona's stock price be in 2018?
6 analysts have issued 1 year price targets for Grifols SA, Barcelona's stock. Their predictions range from $22.00 to $22.00. On average, they expect Grifols SA, Barcelona's share price to reach $22.00 in the next twelve months. View Analyst Ratings for Grifols SA, Barcelona.
Who are some of Grifols SA, Barcelona's key competitors?
Some companies that are related to Grifols SA, Barcelona include Alexion Pharmaceuticals (ALXN), Mylan (MYL), Eisai (ESALY), Incyte (INCY), Teva Pharmaceutical Industries (TEVA), Nektar Therapeutics (NKTR), Sino Biopharmaceut (SBMFF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Genmab As (GNMSF), IPSEN (IPSEY), H. Lundbeck A/S- (HLUYY), bluebird bio (BLUE), Aspen Pharmacare (APNHY), Alkermes (ALKS), Jazz Pharmaceuticals (JAZZ), Seattle Genetics (SGEN) and Beigene (BGNE).
Has Grifols SA, Barcelona been receiving favorable news coverage?
News coverage about GRFS stock has trended positive on Wednesday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Grifols SA, Barcelona earned a media sentiment score of 0.39 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Grifols SA, Barcelona's major shareholders?
Grifols SA, Barcelona's stock is owned by a number of of institutional and retail investors. Top institutional investors include
ARTISAN PARTNERS LIMITED PARTNERSHIP
(3.60%), Alliancebernstein L.P. (1.33%), Bank of New York Mellon Corp (0.90%), Vaughan Nelson Investment Management L.P. (0.42%), BlackRock Inc. (0.29%) and First Trust Advisors LP (0.28%). View Institutional Ownership Trends for Grifols SA, Barcelona.
Which institutional investors are selling Grifols SA, Barcelona stock?
GRFS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, BlackRock Inc., GABELLI & Co INVESTMENT ADVISERS INC., Gabelli Funds LLC, Arrowstreet Capital Limited Partnership, Citadel Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Grifols SA, Barcelona.
Which institutional investors are buying Grifols SA, Barcelona stock?
GRFS stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Engadine Partners LLP, Two Sigma Advisers LP, Two Sigma Investments LP, Vaughan Nelson Investment Management L.P., First Trust Advisors LP, Kornitzer Capital Management Inc. KS and Jefferies Group LLC. View Insider Buying and Selling for Grifols SA, Barcelona.
How do I buy shares of Grifols SA, Barcelona?
Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Grifols SA, Barcelona's stock price today?
One share of GRFS stock can currently be purchased for approximately $21.09.
How big of a company is Grifols SA, Barcelona?
Grifols SA, Barcelona has a market capitalization of $14.51 billion and generates $4.88 billion in revenue each year. The biotechnology company earns $749.04 million in net income (profit) each year or $0.93 on an earnings per share basis. Grifols SA, Barcelona employs 14,877 workers across the globe.
How can I contact Grifols SA, Barcelona?
Grifols SA, Barcelona's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]
MarketBeat Community Rating for Grifols SA, Barcelona (GRFS)MarketBeat's community ratings are surveys of what our community members think about Grifols SA, Barcelona and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Grifols SA, Barcelona (NASDAQ:GRFS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Buy||Buy||Buy|
|Consensus Rating Score: ||2.33||2.75||2.75||2.67|
|Ratings Breakdown: ||1 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$22.00||N/A||N/A||N/A|
|Price Target Upside: ||4.31% upside||N/A||N/A||N/A|
Grifols SA, Barcelona (NASDAQ:GRFS) Consensus Price Target History
Grifols SA, Barcelona (NASDAQ:GRFS) Analyst Ratings History
(Data available from 3/21/2016 forward)
Grifols SA, Barcelona (NASDAQ:GRFS) Earnings History and Estimates Chart
Grifols SA, Barcelona (NASDAQ GRFS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017||Q3 2017||$0.29||$0.29||$1.24 billion||View||N/A|
|7/28/2017||Q2 2017||$0.28||$0.27||$1.19 billion||$1.24 billion||View||N/A|
|5/3/2017||Q1 2017||$0.27||$0.26||$1.14 billion||$1.13 billion||View||N/A|
|2/28/2017||Q4 2016||$0.26||$1.19 billion||View||N/A|
|11/8/2016||Q3 2016||$0.28||$1.12 billion||View||N/A|
|7/28/2016||Q2 2016||$0.27||$0.27||$1.19 billion||$1.12 billion||View||N/A|
|5/5/2016||Q1 2016||$0.24||$0.22||$1.04 billion||$1.06 billion||View||N/A|
|11/4/2015||Q3 2015||$0.22||$0.23||$1.01 billion||$1.08 billion||View||N/A|
|7/30/2015||Q2 2015||$0.23||$0.22||$1.10 billion||View||N/A|
|5/7/2015||Q1 2015||$0.24||$0.25||$972.80 million||$1.02 billion||View||N/A|
|2/26/2015||Q4 2014||$0.29||$0.27||$1.04 billion||View||N/A|
|10/31/2014||Q3 2014||$0.26||$0.22||$1.04 billion||$1.10 billion||View||N/A|
|7/30/2014||Q2 2014||$0.28||$0.20||$1.16 billion||$1.09 billion||View||N/A|
|5/6/2014||Q1 2014||$0.28||$0.25||$1.11 billion||View||N/A|
|2/20/2014||Q4 2013||$0.15||$923.39 million||View||N/A|
|11/5/2013||Q3 2013||$0.17||$881.88 million||View||N/A|
|7/31/2013||Q2 2013||$0.18||$924.58 million||View||N/A|
|5/2/2013||Q1 2013||$0.18||$903.10 million||View||N/A|
Grifols SA, Barcelona (NASDAQ:GRFS) Earnings Estimates
2018 EPS Consensus Estimate: $1.27
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Grifols SA, Barcelona (NASDAQ:GRFS) Dividend Information
|Most Recent Dividend:||6/8/2017|
|Payout Ratio:||30.11% (Trailing 12 Months of Earnings) |
23.53% (Based on This Year's Estimates)
20.90% (Based on Next Year's Estimates)
Grifols SA, Barcelona (NASDAQ:GRFS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Grifols SA, Barcelona (NASDAQ GRFS)
No insider trades for this company have been tracked by MarketBeat.com
Grifols SA, Barcelona (NASDAQ GRFS) News Headlines
|Can Grifols SA. (BME:GRF) Continue To Outperform Its Industry?|
finance.yahoo.com - March 15 at 8:55 AM
|Critical Review: Grifols SA, Barcelona (GRFS) & SIGA Technologies (SIGA)|
www.americanbankingnews.com - March 15 at 1:05 AM
|Grifols SA, Barcelona (GRFS) Lifted to "Hold" at HSBC|
www.americanbankingnews.com - March 14 at 9:02 PM
|Grifols breaks ground on $120M Clayton facility|
finance.yahoo.com - March 14 at 6:13 PM
|Consolidated Research: 2018 Summary Expectations for B Communications, Student Transportation, Aurinia Pharmaceuticals, Grifols, S.A., NEXEO SOLUTIONS, and ASML Holding N.V. — Fundamental Analysis, Key Performance Indications|
finance.yahoo.com - March 13 at 9:14 AM
|Grifols SA, Barcelona (GRFS) Holdings Boosted by Alliancebernstein L.P.|
www.americanbankingnews.com - March 6 at 4:14 AM
|BRIEF-Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S.|
www.reuters.com - March 5 at 5:20 PM
|Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.|
finance.yahoo.com - March 5 at 9:07 AM
|Grifols SA, Barcelona (GRFS) Shares Sold by Arrowstreet Capital Limited Partnership|
www.americanbankingnews.com - March 5 at 4:42 AM
|Grifols SA, Barcelona (GRFS) PT Lowered to $22.00|
www.americanbankingnews.com - March 1 at 6:56 PM
|Grifols SA, Barcelona (GRFS) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - March 1 at 3:34 AM
|Grifols Shines Light on Rare Disease with Launch of Educational Campaign "Look Into Genetic COPD"|
finance.yahoo.com - February 28 at 5:22 PM
|Citadel Advisors LLC Reduces Position in Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - February 28 at 10:52 AM
|FDx Advisors Inc. Acquires 2,558 Shares of Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - February 27 at 12:46 PM
|Sei Investments Co. Has $10.94 Million Stake in Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - February 25 at 6:56 AM
|Grifols SA, Barcelona (GRFS) Shares Sold by Bank of New York Mellon Corp|
www.americanbankingnews.com - February 25 at 4:32 AM
|Technical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBio|
www.bizjournals.com - February 8 at 8:39 AM
|VBI Vaccines (VBIV) & Grifols SA, Barcelona (GRFS) Head-To-Head Analysis|
www.americanbankingnews.com - February 6 at 11:06 PM
|BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment|
www.reuters.com - February 6 at 4:10 PM
|Grifols HyperRAB® (rabies immune globulin ) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection|
finance.yahoo.com - February 6 at 4:10 PM
|Grifols SA, Barcelona (GRFS) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - February 4 at 3:30 AM
|BRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US Assets|
www.reuters.com - January 30 at 9:58 AM
|BidaskClub Lowers Grifols SA, Barcelona (GRFS) to Hold|
www.americanbankingnews.com - January 20 at 10:28 AM
|Grifols SA, Barcelona (GRFS) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - January 10 at 3:08 AM
|Grifols SA, Barcelona (GRFS) Upgraded to "Hold" by Zacks Investment Research|
www.americanbankingnews.com - January 4 at 11:52 PM
|First Week of August 17th Options Trading For Grifols SA - Nasdaq|
www.nasdaq.com - January 3 at 5:11 PM
|Stocks With Rising Relative Price Strength: Grifols|
finance.yahoo.com - January 3 at 5:11 PM
|Grifols SA, Barcelona (GRFS) versus Trillium Therapeutics (TRIL) Financial Comparison|
www.americanbankingnews.com - January 2 at 9:14 PM
|Grifols SA, Barcelona (GRFS) Upgraded by BidaskClub to Hold|
www.americanbankingnews.com - December 28 at 4:56 PM
|Comparing Tetralogic Pharmaceuticals (TLOG) and Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - December 28 at 9:28 AM
|BidaskClub Upgrades Grifols SA, Barcelona (GRFS) to "Sell"|
www.americanbankingnews.com - December 24 at 8:15 AM
|ETFs with exposure to Grifols SA : December 19, 2017|
finance.yahoo.com - December 19 at 5:09 PM
|Reviewing Mateon Therapeutics (MATN) & Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - December 17 at 5:32 AM
|Comparing Anavex Life Sciences (AVXL) and Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - December 16 at 1:30 AM
|Grifols SA : GRFS-US: Dividend Analysis : December 04th, 2017 (record date) : By the numbers : December 11, 2017|
finance.yahoo.com - December 11 at 5:20 PM
|BidaskClub Lowers Grifols SA, Barcelona (GRFS) to Strong Sell|
www.americanbankingnews.com - December 9 at 9:56 AM
|Grifols SA, Barcelona (GRFS) vs. Mateon Therapeutics (MATN) Head-To-Head Contrast|
www.americanbankingnews.com - December 8 at 9:52 AM
|Analyzing Tetralogic Pharmaceuticals (TLOG) & Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - December 7 at 11:42 AM
|ETFs with exposure to Grifols SA : December 5, 2017|
finance.yahoo.com - December 5 at 5:06 PM
|Head-To-Head Analysis: Sevion Therapeutics (SVON) and Grifols (GRFS)|
www.americanbankingnews.com - December 2 at 7:18 PM
|Head-To-Head Comparison: Grifols (GRFS) and Jazz Pharmaceuticals (JAZZ)|
www.americanbankingnews.com - November 29 at 9:08 AM
|Grifols, S.A. (GRFS) Downgraded by UBS AG|
www.americanbankingnews.com - November 24 at 11:18 AM
|Financial Analysis: Grifols, (GRFS) vs. Osiris Therapeutics (OSIR)|
www.americanbankingnews.com - November 23 at 11:18 PM
|Grifols, S.A. (GRFS) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - November 21 at 3:52 AM
|ETFs with exposure to Grifols SA : November 16, 2017|
finance.yahoo.com - November 16 at 2:52 PM
|$0.29 Earnings Per Share Expected for Grifols, S.A. (GRFS) This Quarter|
www.americanbankingnews.com - November 7 at 5:40 PM
|William Blair Analysts Reduce Earnings Estimates for Grifols, S.A. (GRFS)|
www.americanbankingnews.com - November 6 at 5:24 AM
|Visit To Grifols' Headquarters During Tumultuous Time In Catalonia - Seeking Alpha|
seekingalpha.com - November 3 at 9:09 PM
|ETFs with exposure to Grifols SA : November 2, 2017|
finance.yahoo.com - November 2 at 10:32 PM
|Stocks Showing Rising Market Leadership: Grifols Earns 83 RS Rating|
finance.yahoo.com - October 31 at 8:39 PM
Grifols SA, Barcelona (NASDAQ:GRFS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Grifols SA, Barcelona (NASDAQ:GRFS) Income Statement, Balance Sheet and Cash Flow Statement
Grifols SA, Barcelona (NASDAQ GRFS) Stock Chart for Wednesday, March, 21, 2018